Profound Medical Announces Upcoming Investor Events
MWN-AI** Summary
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) has announced its participation in two significant investor events taking place in February 2026. The company, known for its innovative AI-powered, MRI-guided, incision-free therapies for tissue ablation, will engage in one-on-one meetings at the Lake Street Life-Sciences Invitational in Scottsdale, AZ, from February 4-5, and at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT, from February 10-11. As these meetings do not include webcasts, interested parties are encouraged to follow up directly with the company for insights.
Profound Medical is recognized for its flagship product, the TULSA-PRO® system, which offers a precise, real-time MRI-guided procedure aimed at treating various prostate conditions including prostate cancer and benign prostatic hyperplasia (BPH). This advanced technology uses AI-enhanced planning combined with robotically-driven ultrasound to deliver targeted treatment without the need for incisions or radiation. The TULSA Procedure has emerged as a promising solution, boasting benefits such as quick recovery, minimal side effects, and the ability to treat patients in a single session.
Additionally, the company is commercializing Sonalleve®, another innovative platform that is CE marked for the non-invasive treatment of uterine fibroids and other conditions. Sonalleve has also obtained regulatory approval in China and the United States. Profound is actively exploring broader treatment applications for Sonalleve, which may further enhance its portfolio.
These events signify Profound Medical's commitment to engaging with investors and stakeholders as it continues to pioneer advancements in medical devices and therapies. For further information, interested parties can contact Stephen Kilmer in Investor Relations.
MWN-AI** Analysis
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) is positioning itself as a leader in advanced medical technologies through AI-powered, incision-free therapies for treating prostate diseases. The recent announcement about its participation in notable investor events in February underscores the company's commitment to transparency and engagement with the investment community, which can bolster investor confidence.
As the company prepares for one-on-one meetings at the Lake Street Life-Sciences Invitational and the BTIG MedTech Conference, stakeholders should watch closely for insights into its sales performance, market adoption rates, and strategies for expanding its innovative TULSA-PRO and Sonalleve technologies. The TULSA Procedure stands out as a potential game-changer in prostate care due to its precision and minimally invasive nature, addressing a wide patient demographic from those with benign prostatic hyperplasia (BPH) to prostate cancer.
Investors should consider the growing market potential and favorable regulatory approvals that Profound has attained, including CE marking, Health Canada approval, and FDA 510(k) clearance. These milestones enhance the legitimacy of its offerings and may foster increased adoption in clinical settings.
However, it’s essential to remain cautious amid potential market volatility, especially in the healthcare sector, which can be heavily influenced by regulatory changes, competition, and healthcare reimbursement policies. With the company in early-stage exploration of markets for Sonalleve and the increasing demand for non-invasive treatment options, there is a promising pathway for growth.
Holding or initiating a position in Profound Medical may be advisable for investors looking at long-term growth prospects, particularly if future communications from management reveal strong data on patient outcomes or strategic partnerships that could accelerate market penetration. Overall, a careful watch on the outcomes of these investor events will be instrumental for potential investors to gauge Profound’s trajectory in a competitive landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce its participation in the following investor events in February.
- Lake Street Life-Sciences Invitational: Profound is scheduled to participate in a series of one-on-one meetings February 4th-5th in Scottsdale, AZ.
- BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference: The Company is scheduled to participate in a series of one-on-one meetings February 10th-11th in Snowbird, UT.
Due to the format of the events, no webcasts will be available.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. The TULSA Procedure is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with the TULSA Procedure. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ**
What are the anticipated outcomes for Profound Medical Corp. PRN:CC in the upcoming investor meetings in Scottsdale and Snowbird, particularly in terms of securing partnerships or funding?
How does Profound Medical Corp. PRN:CC plan to expand its market presence for TULSA-PRO and Sonalleve in 2026, especially in light of recent regulatory approvals?
Can you elaborate on how Profound Medical Corp. PRN:CC intends to leverage AI technology to differentiate its offerings in the medical device space and drive patient adoption?
What recent clinical data does Profound Medical Corp. PRN:CC have that supports the efficacy and safety of the TULSA Procedure in comparison to traditional prostate treatments?
**MWN-AI FAQ is based on asking OpenAI questions about Profound Medical Corp. (TSXC: PRN:CC).
NASDAQ: PRN:CC
PRN:CC Trading
0.45% G/L:
$11.28 Last:
9,800 Volume:
$11.23 Open:
